PARP1 and cancer: To circumvent this, Professor Alexei Tulin’s lab at Fox Chase Cancer Centre, Philadelphia identified structurally new non-NAD+-like inhibitors that block PARP1 activity in cancer cells with greater efficacy and potency than classical PARP1 inhibitor currently used in the clinical practices [44].